Table 1.
Characteristics of the study patients
| Clinical characteristic | Patient (n = 61) |
|---|---|
| Age | |
| ≥ 65 | 25 |
| < 65 | 36 |
| Gender | |
| Male | 55 |
| Female | 6 |
| Weight | |
| ≥ 60 kg | 23 |
| < 60 kg | 38 |
| BCLC | |
| A | 3 |
| B | 19 |
| C | 39 |
| Child–Pugh | |
| A | 55 |
| B | 6 |
| Tumor numbers | |
| 1 | 12 |
| ≥ 2 | 39 |
| Tumor size (cm) | |
| HBV | |
| Positivity | 57 |
| Negative | 4 |
| AFP (ng/ml) | |
| ≥ 400 | 32 |
| < 400 | 29 |
| GGT (U/L) | |
| ≥ 60 | 45 |
| < 60 | 16 |
| ALP (U/L) | |
| ≥ 125 | 26 |
| < 125 | 35 |
| AST (U/L) | |
| ≥ 40 | 46 |
| < 40 | 15 |
| ALT (U/L) | |
| ≥ 50 | 34 |
| < 50 | 27 |
| ALB (g/L) | 39.1 ± 5.2 |
| TBIL (µmol/L) | 18.9 ± 15.0 |
| PT (s) | 12.4 ± 1.2 |
| NLR | 3.0 ± 1.9 |
| LMR | 4.0 ± 2.1 |
| PLR | 154.6 ± 76.7 |
| PNI | 47.8 ± 7.3 |
| SII | 671.1 ± 565.6 |
AFP, alpha-fetoprotein; AST, aspartate aminotransferase; ALP, alkaline phosphatase; ALT, Alanine aminotransferase. ALB, Albumin; BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; Child–Pugh; GGT, γ-glutamyl transpeptidase;LMR, lymphocyte to monocyte ratio; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; PNI, prognostic nutritional index; PT, Prothrombin time; SII, systemic immune-inflammation index; TBIL, total bilirubin